Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
RCUS

RCUS - Arcus Biosciences Inc Stock Price, Fair Value and News

15.99USD-0.21 (-1.30%)Market Closed

Market Summary

RCUS
USD15.99-0.21
Market Closed
-1.30%

RCUS Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

RCUS Stock Price

View Fullscreen

RCUS RSI Chart

RCUS Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-6.3

Price/Sales (Trailing)

6.14

EV/EBITDA

-5.82

Price/Free Cashflow

-6.19

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

-95.78%

Return on Equity

-32.67%

Return on Assets

-17.87%

Free Cashflow Yield

-16.16%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

237.0M

Rev. Growth (Yr)

480%

Rev. Growth (Qtr)

367.74%

RCUS Earnings

Earnings (TTM)

-231.0M

Earnings Growth (Yr)

95%

Earnings Growth (Qtr)

95.06%

Breaking Down RCUS Revenue

Last 7 days

2.0%

Last 30 days

-5.5%

Last 90 days

-8.7%

Trailing 12 Months

-18.3%

How does RCUS drawdown profile look like?

RCUS Financial Health

Current Ratio

5.22

RCUS Investor Care

Shares Dilution (1Y)

24.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024237.0M000
2023119.0M121.0M120.0M117.0M
2022391.5M409.1M432.6M112.0M
202185.7M93.4M38.4M383.0M
202015.0M15.0M77.8M78.0M
20198.9M9.4M6.8M15.0M
20182.7M3.9M8.0M8.4M
20170001.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arcus Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 15, 2024
jarrett jennifer
sold (taxes)
-215,010
16.97
-12,670
chief operating officer
Jun 15, 2024
rosen terry j
sold (taxes)
-215,010
16.97
-12,670
chief executive officer
Jun 15, 2024
tang carolyn c.
sold (taxes)
-70,968
16.97
-4,182
general counsel
Jun 15, 2024
jaen juan c.
sold (taxes)
-118,264
16.97
-6,969
president
Jun 06, 2024
kaneko yasunori
acquired
-
-
8,400
-
Jun 06, 2024
lambert nicole
acquired
-
-
8,400
-
Jun 06, 2024
falberg kathryn e
acquired
-
-
8,400
-
Jun 06, 2024
lacey david l.
acquired
-
-
8,400
-
Jun 06, 2024
perlman andrew j
acquired
-
-
8,400
-
Jun 06, 2024
machado patrick
acquired
-
-
8,400
-

1–10 of 50

Which funds bought or sold RCUS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-2,063
-
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-29,000
364,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-3,000
301,000
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-77.4
-4,917,180
1,414,280
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.45
-64,887
928,084
-%
May 16, 2024
COMERICA BANK
reduced
-10.95
-57,530
422,893
-%
May 15, 2024
Voya Investment Management LLC
reduced
-43.18
-264,725
339,236
-%
May 15, 2024
SUVRETTA CAPITAL MANAGEMENT, LLC
unchanged
-
-210,606
18,073,900
0.67%
May 15, 2024
Royal Bank of Canada
reduced
-76.96
-77,000
23,000
-%
May 15, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
sold off
-100
-206,032
-
-%

1–10 of 42

Are Funds Buying or Selling RCUS?

Are funds buying RCUS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RCUS
No. of Funds

Unveiling Arcus Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
6.25%
4,680,716
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Jan 31, 2024
gilead sciences, inc.
35%
31,532,781
SC 13D/A
Jan 24, 2024
state street corp
5.66%
4,239,577
SC 13G
Jan 23, 2024
blackrock inc.
13.4%
10,035,170
SC 13G/A
Jul 06, 2023
gilead sciences, inc.
35%
25,586,953
SC 13D/A
Feb 14, 2023
pfm health sciences, lp
3.7%
6
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
1.7%
1,236,002
SC 13G/A
Feb 10, 2023
ecor1 capital, llc
0%
0
SC 13G/A
Feb 09, 2023
vanguard group inc
6.04%
4,373,177
SC 13G

Recent SEC filings of Arcus Biosciences Inc

View All Filings
Date Filed Form Type Document
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading

Peers (Alternatives to Arcus Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

Arcus Biosciences Inc News

Latest updates
MarketBeat38 hours ago

Arcus Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue367.7%145,000,00031,000,00032,000,00029,000,00025,000,00034,000,00033,000,00027,000,00018,000,000354,617,0009,461,0009,461,0009,461,0009,970,00064,530,0001,750,0001,750,0009,750,0001,750,0001,750,0001,750,000
Operating Expenses32.0%161,000,000122,000,000112,000,000112,000,000111,000,000108,000,000103,000,00096,000,00085,000,00073,598,00087,597,00085,597,00082,208,00061,499,00062,978,00047,125,00030,150,00027,277,00024,999,00030,910,00020,523,000
  S&GA Expenses10.3%32,000,00029,000,00030,000,00028,000,00030,000,00028,000,00026,000,00026,000,00024,000,00023,010,00016,343,00016,826,00015,821,00013,383,00011,177,00011,432,0007,008,0006,590,5007,758,0005,911,0004,969,000
  R&D Expenses17.2%109,000,00093,000,00082,000,00084,000,00081,000,00080,000,00077,000,00070,000,00061,000,00050,588,00071,254,00068,771,00066,387,00048,364,00051,801,00035,693,00023,142,00020,686,50017,241,00024,999,00015,554,000
EBITDA Margin63.3%-0.92-2.50-2.35-2.29-2.27-2.320.210.180.170.15-3.12-1.28---------
Income Taxes-100.0%-1,000,0002,000,0001,000,0002,000,000---1,000,0002,000,000-----------
Earnings Before Taxes95.0%-4,000,000-80,000,000-69,000,000-74,000,000-78,000,000-67,000,000-65,000,000-67,000,000-67,000,000281,538,000-77,975,000-75,970,000-72,593,000--------
EBT Margin62.8%-0.96-2.57-2.40-2.35-2.33-2.370.190.170.150.14-3.21-1.32---------
Net Income95.1%-4,000,000-81,000,000-71,000,000-75,000,000-80,000,000-67,000,000-65,000,000-67,000,000-68,000,000279,538,000-77,975,000-75,970,000-72,593,000-51,853,0001,822,000-45,074,000-27,753,000-16,598,000-22,352,000-28,090,000-17,670,000
Net Income Margin62.9%-0.97-2.62-2.44-2.37-2.34-2.380.180.160.150.14-7.26-2.13---------
Free Cashflow93.6%-6,000,000-94,000,000-73,000,000-62,000,000-101,000,000-70,000,000-83,000,000-66,000,000651,000,000-70,360,000-61,615,000-80,068,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets18.1%1,2931,0951,1911,2201,2541,3451,3941,4771,5431,592839899935772811481176203217239259
  Current Assets28.0%1,0648318829861,0151,0671,1011,2271,2641,262545746842736797472166193200228245
    Cash Equivalents45.7%18512718423023820621827354914817932039017322228567.0058.0079.0076.0068.00
  Net PPE0%51.0051.0050.0045.0037.0035.0034.0033.0033.0032.0029.0024.0015.0011.009.008.009.009.0010.0010.0011.00
Liabilities-------69572974775029729427027026753.0036.0039.0040.0042.0037.00
  Current Liabilities10.9%20418420018017919317716416116614313013212216340.0021.0023.0021.0027.0019.00
Shareholder's Equity53.0%707462520566600657699747797842543605665502544429141164177197222
  Retained Earnings-0.5%-853-849-768-697-622-542-474-409-343-275-554-476-400-328-276-278-233-205-188-166-138
  Additional Paid-In Capital-------1,1831,1651,1451,1181,0971,0811,066830821707373369366363360
Shares Outstanding20.4%91.0076.0075.0075.0073.0073.0072.0072.0071.0069.0070.0068.00---------
Float----1,068---1,298---1,379---1,250---298-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations97.7%-2,000-88,000-63,000-57,000-98,000-70,000-81,000-65,000654,000-61,932-53,757-73,995-66,316-50,050216,265-23,938-31,277-9,471-27,399-19,753-16,839
  Share Based Compensation11.1%20,00018,00018,00018,00019,00017,00016,00015,00017,00014,28714,58513,36712,7618,0666,0024,4703,4622,4372,7402,1301,674
Cashflow From Investing-703.6%-169,00028,00011,00026,000129,00047,00023,000-215,000-268,00018,782-88,6113,00362,826136-387,119-87,07340,056-12,10430,36426,67314,279
Cashflow From Financing7533.3%229,0003,0006,00023,0001,00011,0003,0004,00015,00011,3311,3182,231222,1202,002107,518328,870610520-41.00649-5.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RCUS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 145$ 25
Operating expenses:  
Research and development (Net of recoveries of $16 and $33 from a related party)10981
General and administrative3230
Impairment of long-lived assets200
Total operating expenses161111
Loss from operations(16)(86)
Non-operating income (expense):  
Interest and other income, net139
Effective interest on liability for sale of future royalties(1)(1)
Total non-operating income, net128
Loss before income taxes(4)(78)
Income tax expense0(2)
Net loss$ (4)$ (80)
Net loss per share, basic (in dollars per share)$ (0.05)$ (1.09)
Net loss per share, diluted (in dollars per share)$ (0.05)$ (1.09)
Shares used to compute loss per share, basic (in shares)86.273.0
Shares used to compute loss per share, diluted (in shares)86.273.0
License and Development Services Revenue  
Revenues:  
Total revenues$ 135$ 17
Other Collaboration Revenue  
Revenues:  
Total revenues$ 10$ 8

RCUS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 185$ 127
Marketable securities810632
Receivable from collaboration partners ($21 and $20 from a related party)3538
Prepaid expenses and other current assets3434
Total current assets1,064831
Long-term marketable securities100107
Property and equipment, net5151
Other noncurrent assets ($— and $6 from a related party)78106
Total assets1,2931,095
Current liabilities:  
Accounts payable1617
Deferred revenue ($112 and $84 to a related party)12491
Other current liabilities6476
Total current liabilities204184
Deferred revenue, noncurrent ($209 and $291 to a related party)242307
Other noncurrent liabilities140142
Commitments
Stockholders’ equity:  
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 90.9 shares in 2024 and 75.5 shares in 2023 issued and outstanding1,5611,311
Accumulated deficit(853)(849)
Accumulated other comprehensive loss(1)0
Total stockholders’ equity707462
Total liabilities and stockholders’ equity$ 1,293$ 1,095
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
 CEO
 WEBSITEarcusbio.com
 INDUSTRYBiotechnology
 EMPLOYEES500

Arcus Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Arcus Biosciences Inc? What does RCUS stand for in stocks?

RCUS is the stock ticker symbol of Arcus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcus Biosciences Inc (RCUS)?

As of Tue Jun 18 2024, market cap of Arcus Biosciences Inc is 1.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCUS stock?

You can check RCUS's fair value in chart for subscribers.

What is the fair value of RCUS stock?

You can check RCUS's fair value in chart for subscribers. The fair value of Arcus Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcus Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RCUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RCUS is over valued or under valued. Whether Arcus Biosciences Inc is cheap or expensive depends on the assumptions which impact Arcus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCUS.

What is Arcus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, RCUS's PE ratio (Price to Earnings) is -6.29 and Price to Sales (PS) ratio is 6.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCUS PE ratio will change depending on the future growth rate expectations of investors.